US Press release

media

Press releases

Find out more about Ferring latest announcements.

Press releases

  • COMPANY STATEMENT

    Ferring Position on Alabama Supreme Court Ruling in LePage v Mobile Infirmary Clinic

    - by robthingee

    Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility Association and others and strongly opposes any action that restricts or impairs a person’s ability to fully access in vitro fertilization (IVF) – a well-established medical procedure, which helps couples and individuals realize their dreams of becoming parents. Ferring believes […]

  • PRESS RELEASE 2024

    Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting

    - by robthingee

    Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium in San Francisco Study evaluating effectiveness, overall experiences, patterns of use, and safety of the first and only FDA-approved intravesical gene therapy Final results from ongoing post-marketing study are expected by the end of 2026 Parsippany, NJ – January 24, 2024 […]

  • PRESS RELEASE 2024

    Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.

    - by robthingee

    Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy With full supply of ADSTILADRIN ahead of schedule, Ferring ends the temporary ADSTILADRIN Early Experience Program Enrollment in ABLE-41 U.S. Real-World Evidence Study is ongoing Parsippany, NJ – January 16, 2023 – Ferring Pharmaceuticals today announced that ADSTILADRIN® (nadofaragene firadenovec-vncg) […]